Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancer
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116933 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Nicole D Hildebrand und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Surgery, Institute of Nutrition and Translat…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Body Composition, Carcinoma, Pancreatic Ductal, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Cancer Research Fund International, World Cancer Research Fund.
Abstract (Originalsprache)
INTRODUCTION: Most present-day survival-models of patients with cancer do not account for tumor-host interactions. We hypothesized that host phenotypes based on systemic inflammation and body composition are prognostic of overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: We performed a post-hoc analysis of the nationwide PORSCH-trial, including all patients undergoing pancreatoduodenectomy for PDAC. Primary outcome was OS. Body composition analysis was performed using automatic segmentation (Mosamatic™) of preoperative abdominal computed tomography scans. Low muscle mass and myosteatosis were defined using log-rank stratification of sex-standardized Z-values of skeletal muscle index and radiation attenuation, respectively. Patients were clustered in eight host phenotypes based on combinations of adverse host factors: [1] low muscle mass, [2] myosteatosis, [3] systemic inflammation (C-reactive protein >6mg/L). Their association with OS was tested using multivariable-adjusted Cox-proportional hazard-analysis. Distinct combinations of adverse host factors were stratified into low-, intermediate-, and high-risk phenotypes according to k-means clustering based on log hazard-ratio's. RESULTS: 549 patients were included. The high-risk phenotype, characterized by the presence of all adverse host factors, showed lower median OS than intermediate ([1], [2], [1 +2], [1 +3], [2 +3]) and low-risk ([3]; none) phenotypes (13.0 months [95%CI 11.4-19.3] vs. 21.9 months [95%CI 19.3-24.7] vs. 35.2 months [95%CI 29.2-45.3], respectively; p < 0.001). In multivariable analysis, host phenotypes were associated with OS (adjusted [a]HR 1.39 [95%CI 1.08-1.80, p = 0.01; aHR 2.10 [95%CI 1.53-2.88], p < 0.01, for intermediate- and high-risk respectively), independent of tumor stage. DISCUSSION: Host phenotypes based on body composition and systemic inflammation predict OS independent of tumor stage in patients with resected PDAC, underscoring the importance of tumor-host interactions for clinical survival prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Surgery, Institute of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastric…
- Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, the Netherlands; Laboratory of Medical Oncology, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherland…
- Department of Surgery, Regional Academic Cancer Center Utrecht, St. Antonius Hospital Nieuwegein, University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center, Maastricht, the Netherlands.
- Department of Surgery, Institute of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, the Netherlands.
Förderung
- World Cancer Research Fund International
- World Cancer Research Fund
Zitieren
APA
Hildebrand, N. D., van Dijk, D. P. J., Puik, J. R., Henry, A. C., Andel, P., Dekker, E. N., Michiels, N., Brandts, L., Brecheisen, R., Wee, L., Festen, S., Bosscha, K., Schreinemakers, J. M. J., Wit, F., van der Kolk, M. B., Mieog, J. S. D., Liem, M. S. L., Nieuwenhuijs, V. B., de Hingh, I. H. J. T., …, & Dutch Pancreatic Cancer Group (DPCG) (2026). Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116933
Vancouver
Hildebrand ND, van Dijk DPJ, Puik JR, Henry AC, Andel P, Dekker EN, et al. Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancer. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116933
BibTeX
@article{Hildebrand2026,
author = {Hildebrand, Nicole D and van Dijk, David P J and Puik, Jisce R and Henry, Anne Claire and Andel, Paul and Dekker, Esther N and Michiels, Nynke and Brandts, Lloyd and Brecheisen, Ralph and Wee, Leonard and Festen, Sebastiaan and Bosscha, Koop and Schreinemakers, Jennifer M J and Wit, Fennie and van der Kolk, Marion B and Mieog, J Sven D and Liem, Mike S L and Nieuwenhuijs, Vincent B and de Hingh, Ignace H J T and de Vos-Geelen, Judith and Siveke, Jens T and Klaase, Joost M and de Meijer, Vincent E and de Haas, Robbert J and Groot Koerkamp, Bas and Zonderhuis, Babs M and Kazemier, Geert and Besselink, Marc G and Molenaar, I Quintus and Daamen, Lois A and den Dulk, Marcel and Rensen, Sander S and van Santvoort, Hjalmar C and Olde Damink, Steven W M and Dutch Pancreatic Cancer Group (DPCG), Dutch Pancreatic Cancer Group (DPCG)},
title = {Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancer},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116933}
}
EUVIMED